How PBMCs Can Help During the Detection of Breast Cancer

Breast cancer is the most common malignant tumor among women. Only lung cancer surpasses its mortality rate.

Despite being the most commonly diagnosed cancer worldwide, it’s still detected at late stages very often, with biopsy being the leading diagnostic method. This calls for a more modern approach to tumor detection.

Blood-based approaches, including PBMC analysis, are being investigated as potential tools for identifying immune signatures associated with breast cancer and improving understanding of tumor biology.

By locating and researching cancer PBMCs, scientists can facilitate early screening and diagnosis of patients and even predict tumor development.

Current State of Breast Cancer Diagnosis and Treatment

Mammography remains a standard screening method, although it has limitations, including reduced sensitivity in some populations and the possibility of false-positive or false-negative results.

For example, it has high-intensity radiation during every screening. When assumed, the most common clinical diagnosis remains tissue biopsy, which is highly invasive and is usually prescribed extremely late.

When detected, the condition presents a huge array of characteristics and types.

Four biomarkers are commonly used when classifying and treating breast cancer:

• estrogen receptor (ER);
• progesterone receptor (PR);
• human epidermal growth factor receptor 2 (HER2);
• the proliferation marker Ki67.

Despite various treatment options being available, the tumor heterogeneity doesn’t allow for their optimal usage. With the addition of many new influences on cancer profiles, such as microplastics and air pollution, it’s essential to research and try new detection approaches.

They should be non-invasive and offer detection at an earlier stage. PBMCs could match this approach.

PBMCs as Early Detection Biomarkers for Breast Cancer

PBMCs have been used for oncology research for decades. Since they can interact with tumor antigens and make changes to the gene profile, they can become a new way to detect breast cancer.

Laboratory technicians can utilize PBMCs as biomarkers by researching chromatin open regions and the patterns of chromatin accessibility.

Access to properly processed PBMC samples from suppliers such as Preci can support research into breast cancer biomarkers and immune-related changes.

For instance, MicroRNA-155 (miR-155) is an active participant in tumor progression and inflammation of the human organism. It can also inhibit IL-6, causing a variety of carcinogenic effects in the tumor.

In PBMCs of patients in the early stages of breast cancer, miR-155 is prevalent, closely correlating with tumor grade and ductal carcinoma type.

This means PBMCs as biomarkers could potentially be used in early-stage detection, as well as in the inflammatory stage of breast cancer.

Yet, PBMCs in oncology research also have their limitations. It’s important to make a better connection between the approach and the condition during large-scale studies. Follow-up studies should also be conducted to see the disease outcomes and patient survival rate.

PBMCs Could Be the Future of Breast Cancer Diagnosis

Breast cancer detection currently depends on X-rays and biopsy, which can be harmful and invasive. To progress toward early-stage diagnosis and effective treatment, it’s essential to find a new approach to detection.

PBMCs as biomarkers show a clear connection to tumor development and inflammation in breast cancer patients.

Yet, it still has limitations. This includes the lack of standardization and large-scale studies, which would make it possible to use in clinical practice.